AbbVie (NYSE:ABBV) Shares Down 2.5% - Here's Why

Key Points

• Shares down 2.5% intraday to about $219.73 with volume ~21% below average, leaving the stock slightly below its 50- and 200-day moving averages around $224.5 and a market cap near $388.5 billion.
• Mixed clinical and analyst catalysts: RBC initiated coverage with an Outperform/$260 target and AbbVie reported promising Phase 1 data for ABBV‑295 and progress on risankizumab, but face a near-term headwind after UCB’s Bimzelx beat Skyrizi in psoriatic arthritis.
• Fundamentals and shareholder moves: AbbVie beat quarterly EPS estimates ($2.71 vs. $2.65) and set FY2026 guidance of $14.37–$14.57, declared a $1.73 quarterly dividend (3.1% yield, 293% payout ratio), while insiders trimmed holdings and institutions own ~70% of the stock.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s stock price traded down 2.5% during mid-day trading on Friday . The stock traded as low as $219.44 and last traded at $219.7260. 5,664,082 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 7,179,175 shares. The stock had previously closed at $225.37.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital initiated coverage with an Outperform and a $260 price target, highlighting that AbbVie’s Skyrizi and Rinvoq growth and early immunology momentum still leave upside for investors. RBC Capital Says AbbVie Growth Story Is Still in Early Stages
• Positive Sentiment: AbbVie reported encouraging Phase 1 data for ABBV‑295, a pipeline asset that, if validated, could add to diversification beyond its current franchise. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology development that supports medium‑term growth assumptions. AbbVie Advances Risankizumab Dosing Study
• Positive Sentiment: Allergan Aesthetics (AbbVie business) named a top New York provider again, a small but positive signal for market presence in the aesthetics franchise. Allergan Aesthetics Recognition
• Neutral Sentiment: Analysts maintain a generally constructive view: a consensus “Moderate Buy” sits alongside mixed price targets, leaving sentiment balanced. AbbVie Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Market commentary shows split views — modest model changes but divergent analyst takes on immunology upside vs. competition risk, keeping the outlook nuanced. Narrative for AbbVie Is Shifting
• Neutral Sentiment: Industry research forecasts growth in bipolar depression and psychiatric therapies, a potential longer‑term market tailwind for relevant assets. Bipolar Depression Market Report
• Negative Sentiment: Clinical competition hit: UCB’s Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis, a direct competitive loss that raises near‑term sales and market‑share concerns for a key growth driver. Skyrizi Beaten by Bimzelx
• Negative Sentiment: Pay disclosure shows AbbVie CEO total compensation jumping above $30M, a governance/PR headwind that can weigh on sentiment for some investors. CEO Pay Spike

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ABBV shares. HSBC raised AbbVie from a "hold" rating to a "buy" rating and increased their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Evercore lowered their price target on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research note on Wednesday, February 4th. Scotiabank assumed coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a "sector outperform" rating and a $280.00 price target on the stock. Piper Sandler lifted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $253.15.

AbbVie Stock Down 2.5%

The company has a market capitalization of $388.51 billion, a P/E ratio of 93.10, a P/E/G ratio of 0.79 and a beta of 0.34. The firm has a fifty day simple moving average of $224.52 and a 200-day simple moving average of $224.48.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the firm posted $2.16 earnings per share. AbbVie's revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie's payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

Institutional Trading of AbbVie

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the last quarter. State Street Corp lifted its position in shares of AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company's stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC boosted its holdings in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Finally, Bank of America Corp DE grew its position in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock valued at $5,900,617,000 after purchasing an additional 356,394 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.